Last updated 2026-08-12
- Raised $36M Series A, Aug 2026
- Raised $10M Seed round led by NFX, May 2024
Total raised
$46.0M
Last: A Round 2026-08
Stage
Series A
Founded
2022
Headcount
—
HQ
Ramat Gan, Israel
Sector
Health Tech & Life Sciences
About
Remepy is an Israeli startup pioneering a new category of therapy called "hybrid drugs." These drugs combine traditional pharmaceuticals with targeted digital interventions delivered via a mobile application. The company's mission is to deliver more personalized, adaptive, and effective care by uniting biology, behavior, and technology to help patients heal. Remepy's digital molecules are designed to trigger physiological effects through the brain, enhancing the effectiveness of traditional drugs. The company is initially targeting Parkinson's Disease with its Hybridopa product, and also exploring applications in neurodegenerative diseases, cancer, autoimmune diseases, and degenerative eye diseases.
Funding history · 2 rounds · $46.0M total
2 events/rounds · $46.0M Total Funding: $46.0M in Private Equity
Aug 2026
May 2024
Offices
Ramat Gan, Israel · HQ / main office
Q&A
- What is Remepy's core business?
- Remepy is an Israeli startup that develops "hybrid drugs" by combining traditional pharmaceuticals with targeted digital interventions delivered via a mobile application. The company aims to provide personalized, adaptive, and effective care by integrating biology, behavior, and technology.
- When was Remepy founded and where is its headquarters?
- Remepy was founded in 2022 and is headquartered in Ramat Gan, Israel.
- How much funding has Remepy raised to date?
- Remepy has raised a total of $62,000,000 USD across multiple funding rounds.
- When was Remepy's most recent funding round and how much was raised?
- Remepy's most recent funding round was a C Round in August 2026, which raised $36,000,000 USD.
- Which investors participated in Remepy's Seed round?
- In November 2022, Remepy secured Seed funding with Fresh Fund.
- Who are the co-CEOs of Remepy?
- Dr. Michal Tsur and Or Shoval are the co-CEOs of Remepy.
- What is Remepy's primary target disease area for its hybrid drugs?
- Remepy is initially targeting Parkinson's Disease with its Hybridopa product, and is also exploring applications in other neurodegenerative diseases, cancer, autoimmune diseases, and degenerative eye diseases.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2BB2B2C
Highlights
Patents
Tags
digital-healthcaresaasdrug-discoverydrug-developmentpharmaceuticalsbiotechnologyhealth-techartificial-intelligence
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | remepy.com/ |
|---|---|
| linkedin.com/company/82435157 |
Identifiers & details
| Founded | 2022 |
|---|---|
| Status reason | registrar: מחוסלת מרצון |
Radar intelligence
Patents
| EPO | 3 |
|---|
Publications (Crossref)
| Works | 2 |
|---|
GitHub
| Top repos | research-pages, flutter-plugins, better_player_plus, flutter_packages, betterplayer |
|---|
App Store
| App | Rating | Ratings |
|---|---|---|
| TGCT & Me |
Web history (Wayback)
| Domain | remepy.com |
|---|
Certificate / subdomain footprint
| Subdomains | 9 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516671476 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2022-08-29 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 2 — charge (2) |
| Registered address | תובל 40 רמת גן |
Recent registry events
| Date | Event |
|---|---|
| 2025-12-31 | רישום שעבוד |
| 2026-05-13 | סילוק שעבוד |